Abstract: This paper investigates the determinants of ownership changes of drug candidates in one of the most important current pharma markets —the market for diabetes. We in particular look at how do the competitive circumstances, progress in clinical development and radicalness of the drug candidates matter in these decisions. We use newly constructed, very granular dataset tracking the development, ownership and patenting histories of each drug candidate undertaken in the diabetic R&D landscape between 1997-2017. The results of this research should help to understand the implications these transactions have for innovation outcomes in the market for diabetes.
Joint with Melissa Newham, Jo Seldeslachts (DIW Berlin & KU Leuven), and Reinhilde Veugelers (KU Leuven)